Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REPLATINUM: A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer

NCT05566041 is registered in ClinicalTrials.gov with EpicentRx, Inc. as lead sponsor.

NCT NCT05566041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05566041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REPLATINUM: A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer
Lead sponsor
EpicentRx, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 1, 2022
Completion date
December 31, 2025
Enrollment
292 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, small cell lung